Clinical trials: Human Papillomavirus Positive Cervical Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma
A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), HPV (Human Papillomavirus)-Associated Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06797986
- Testing
- BVAC-E6E7 (low level), BVAC-E6E7 (high level), BVAC-E6E7 (RP2D)
- Where
- 2 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Cellid Co., Ltd.
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Oropharyngeal Carcinoma
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for…
- Trial name
- NCT06984861
- Testing
- 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires
- Where
- 7 sites in United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, HPV
Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier
Cervical cancer remains a major public health challenge in low- and middle-income countries (LMICs) due to financial and logistical issues.
- Trial name
- NCT04859530
- Testing
- AVC test
- Where
- Cameroon
- Volunteers
- 5,886 people, healthy volunteers welcome
- Sponsor
- Prof. Patrick Petignat
Head and Neck Carcinoma, Adult Disease
Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer
This study is a multicentric double-blind placebo-controlled dose escalation trial of a CD40HVac vaccine (humanized anti-CD40 mAb fused to HPV16 E6/E7 oncoproteins) adjuvanted with poly-ICLC (Hiltonol) in patients with HPV16…
- Trial name
- HPVDCVax (NCT06007092)
- Testing
- HPVDC injection level dose 1, HPVDC injection level dose 2
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
HPV-Related Squamous Cell Carcinoma
A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers
This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts…
- Trial name
- NCT04180215
- Testing
- HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab.
- Where
- 34 sites in United States, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Hookipa Biotech GmbH
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This is a global, multi-center, Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs.
- Conditions
- Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE-003 (NCT06790966)
- Testing
- Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
- Where
- 28 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Some cancers may be related to an infection with a virus, such as the Human Papilloma Virus (HPV). HPV related Oropharyngeal cancer (HPVOPC) accounts for 80% of oropharynx cancer cases in the United States.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02002182
- Testing
- ADXS11-001 (ADXS-HPV)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Sikora
Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma
Oral Rigosertib for Squamous Cell Carcinoma
The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT01807546
- Testing
- rigosertib
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Traws Pharma, Inc.
HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous…
- Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT07628062
- Testing
- Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel
- Volunteers
- 70 people
- Sponsor
- ImmunityBio, Inc.
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Digital Telecytology for Triage of HPV-Positive Women in Cameroon
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon.
- Conditions
- Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Cancer Screening Methods
- Trial name
- NCT07550010
- Testing
- HPV testing (self-sampling), Digital telecytology, AI-assisted telecytology
- Where
- 2 sites in Cameroon
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Cervical Cancer, Pathological Screening Smear
Comparison of 2 Types of Cervical Specimens in Patients With a Pathological Screening Smear
The recommendations on the method and the realization of the cervico-uterine smears are clear. With regard to performing endocervical curettage, several methods are possible without precise consensus.
- Trial name
- ENDOCOL (NCT04000477)
- Testing
- Cytobrush, Kevorkian curette
- Where
- France
- Volunteers
- 3 people
- Sponsor
- University Hospital, Lille
Cervical Cancer
CINtec PLUS Triage in HPV Primary Screening
Prospective study which will recruit participants when they attend for a routine cervical screening. The study will evaluate the use of CINtec PLUS for triage of human papillomavirus (HPV) positive participants in HPV primary…
- Trial name
- NCT03721484
- Testing
- CINtec PLUS
- Where
- United Kingdom
- Volunteers
- 9,800 people, healthy volunteers welcome
- Sponsor
- Western Health and Social Care Trust
Cervical Precancerous Lesions, Cervical Cancer
TS Triage of HR-HPV Positive Population and Its Accuracy Study
A prospective study assessing TS accuracy in HR-HPV+ women, influencing factors, and 1-year follow-up of false-positives versus biopsy.
- Trial name
- NCT07777094
- Testing
- Colposcopy and cervical biopsy, Follow-up of TS false-positive patients
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital of Nantong University
Human Papillomavirus Infection, Cervical Cancer
Primary Cervical Cancer Screening by Self-sampling HPV Test
Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider…
- Conditions
- Human Papillomavirus Infection, Cervical Cancer, Negative For Intraepithelial Lesion Or Malignancy, Atypical Squamous Cells of Undetermined Significance
- Trial name
- PREVENT (NCT05613283)
- Where
- 6 sites in China
- Volunteers
- 17,875 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
HIV (Human Immunodeficiency Virus), HPV
Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general…
- Conditions
- HIV (Human Immunodeficiency Virus), HPV, Cervical Precancer
- Trial name
- NCT07468695
- Testing
- Thermal ablation (TA) with 1 probe, Thermal ablation (TA) with 2 probes
- Where
- Kenya
- Volunteers
- 300 people
- Sponsor
- Fred Hutchinson Cancer Center
Cervical Intraepithelial Neoplasia, Cervical Cancer
HPV Integration Testing for Human Papillomavirus-Positive Women
Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence.
- Trial name
- NCT02576262
- Testing
- TCT，HPV，colposcopic inspection
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
This phase I trial studies the side effects of nivolumab and IRX-2 and how well they work in treating participants with stage III-IVA oral cavity cancer or human papillomavirus (HPV)-positive oropharyngeal cancer that can be…
- Conditions
- Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT03575234
- Testing
- Cyclophosphamide, IRX-2, Nivolumab
- Where
- 2 sites in United States
- Sponsor
- Emory University